Emerging Role of Low-dose Loop Diuretics in the Management of Heart Failure Patients to Maintain Euvolemia.
低劑量環利尿劑在心衰竭患者維持正常血容量管理中的新興角色。
J Assoc Physicians India 2024-09-18
[Canagliflozin can improve cardiac function in HFpEF rats partly by regulating ferroptosis].
Canagliflozin 可以通過調節鐵死亡部分改善 HFpEF 大鼠的心臟功能。
Zhonghua Xin Xue Guan Bing Za Zhi 2024-09-18
Bradycardia-induced heart failure with preserved ejection fraction successfully treated with empagliflozin and theophylline: a case report.
心動過緩引起的保留射血分數心衰竭成功治療案例：使用 empagliflozin 和 theophylline。
Eur Heart J Case Rep 2024-09-17
Comparison of kidney and hepatic outcomes among sodium-glucose cotransporter-2 inhibitors: a retrospective study using multiple propensity scores.
鈉-葡萄糖共轉運蛋白-2 抑制劑在腎臟和肝臟結果的比較：使用多重傾向評分的回顧性研究。
J Pharm Health Care Sci 2024-09-16
Sodium-glucose cotransporter 2 inhibitors and renal cancer in the US FDA adverse event reporting system.
美國 FDA 不良事件報告系統中鈉-葡萄糖共轉運蛋白 2 抑制劑與腎癌的關聯。
Eur J Clin Pharmacol 2024-09-16
Pipeline of New Drug Treatment for Non-alcoholic Fatty Liver Disease/Metabolic Dysfunction-associated Steatotic Liver Disease.
非酒精性脂肪肝病/代謝功能障礙相關脂肪肝病的新藥治療管道。
J Clin Transl Hepatol 2024-09-16
Synergistically improved cardiovascular outcomes in type 2 diabetes mellitus patients with combined treatment of SGLT-2 inhibitors and pioglitazone.
SGLT-2 抑制劑與 pioglitazone 聯合治療對 2 型糖尿病患者心血管結果的協同改善。
Front Endocrinol (Lausanne) 2024-09-16